Referenced in: none

Automatically associated channels: Kv1.5

Title: 32nd national medicinal chemistry symposium - medicinal chemistry developments for neurodegeneration, diabetes and cancer.

Authors: Deborah Gater

Journal, date & volume: IDrugs, 2010 Aug , 13, 514-6

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/20721817

Abstract
The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on NR2B subtype-selective NMDA receptor antagonists from Merck; selective neuronal nitric oxide synthase inhibitors from Northwestern University; novel GPR119 agonists, suchas GSK-1292263A (GlaxoSmithKline plc), PSN-821 ((OSI) Prosidion) and MBX-2982 (Metabolex Inc); a small-molecule Bcl inhibitor,navitoclax (Abbott Laboratories); and p53-targeting agents from sanofi-aventis and Ascenta Therapeutics Inc, including AT-219.